Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin aspart.

K L Simpson1, C M Spencer

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 3, 1999
PubMed
Summary
This summary is machine-generated.

Insulin aspart, a rapid-acting insulin analogue, offers improved post-meal glucose control and reduced hypoglycemia risk in type 1 diabetes patients compared to human insulin. It achieves faster insulin absorption and higher glucose infusion rates, enhancing overall glycemic management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.

European journal of cancer (Oxford, England : 1990)·2019
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Insulin therapy is crucial for managing diabetes mellitus.
  • Rapid-acting insulin analogues aim to improve glycemic control, particularly postprandially.
  • Insulin aspart is a recombinant analogue designed for faster absorption than human insulin.

Purpose of the Study:

  • To compare the pharmacokinetic and pharmacodynamic profiles of insulin aspart and human insulin.
  • To evaluate the efficacy of insulin aspart in controlling postprandial glucose excursions in type 1 diabetes.
  • To assess the impact of insulin aspart on overall glycemic control and hypoglycemia frequency.

Main Methods:

  • Subcutaneous injection of insulin aspart and human insulin (0.15-0.2 U/kg).

Related Experiment Videos

  • Euglycaemic glucose clamp testing in healthy individuals.
  • Assessment of serum insulin concentrations, glucose infusion rates, and glycemic parameters in type 1 diabetes patients.

    • Main Results:

    • Insulin aspart demonstrated significantly faster absorption and higher peak serum concentrations than human insulin.
    • Higher glucose infusion rates and earlier maximal concentrations were observed with insulin aspart.
    • Reduced postprandial glucose excursions, improved daytime glucose control, and a lower frequency of hypoglycemia were noted with insulin aspart in type 1 diabetes patients.

    Conclusions:

    • Insulin aspart offers a pharmacokinetic and pharmacodynamic advantage over human insulin.
    • Insulin aspart provides superior postprandial glucose control and a reduced risk of hypoglycemia in type 1 diabetes.
    • Insulin aspart represents an effective therapeutic option for enhancing glycemic management in diabetic patients.